
    
      The decision to discontinue the F7TRAUMA-1711 trial is not due to any safety concerns. The
      result of the pre-planned futility analysis performed in June 2008 predicted a very low
      likelihood of reaching a successful outcome on the primary efficacy endpoint at the end of
      the trial and as a consequence, the company has decided to close the trial as this juncture.
    
  